Therapix Biosciences LTD. – American Depositary SH (NASDAQ:TRPX) Sellers Decreased By 16.71% Their Shorts

Therapix Biosciences LTD. – American Depositary SH (NASDAQ:TRPX) had a decrease of its shares shorted by 16.71%. It was announced in February by FINRA the 175,900 shares shorted on TRPX. The 211,200 previous shares are down with 16.71%. 1 days will cost TRPX with 224,300 average volume to restore its former position. 5.88% is Therapix Biosciences LTD. – American Depositary SH float short.

The stock decreased 1.27% or $0.05 during the last trading session, hitting $3.9.Therapix Biosciences Ltd. has volume of 36,867 shares. Since February 10, 2018 TRPX has risen 2.08% and is uptrending. TRPX outperformed by 2.08% the S&P500.

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules.The firm is valued at $13.64 million. The Company’s drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome ; and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment.Currently it has negative earnings. Therapix Biosciences Ltd. has a product development agreement with Cure Pharmaceutical to develop cannabinoid product for sleep disorders.

For more Therapix Biosciences Ltd. (NASDAQ:TRPX) news announced recently go to:,,, or The titles are as follows: “56 Biggest Movers From Yesterday – Benzinga” announced on February 05, 2019, “Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd. – GlobeNewswire” on July 11, 2018, “30 Stocks Moving In Thursday’s Pre-Market Session – Benzinga” with a publish date: August 30, 2018, “Fresh Off IPO, Therapix Biosciences Already Aiming at Tourette’s Phase 3 Trial – 24/7 Wall St.” and the last “Therapix Biosciences (TRPX) Terminates FSD Acquisition LOI –” with publication date: December 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.